BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34584457)

  • 1. Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.
    Li D; Zhang J; Wu L; Yang X; Chen Z; Yuan J
    Cancer Manag Res; 2021; 13():7311-7323. PubMed ID: 34584457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RPP40 is a prognostic biomarker and correlated with tumor microenvironment in uterine corpus endometrial carcinoma.
    Tang J; Tian X; Min J; Hu M; Hong L
    Front Oncol; 2022; 12():957472. PubMed ID: 36091104
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
    Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel cuproptosis-related gene signature for overall survival prediction in uterine corpus endometrial carcinoma (UCEC).
    Lin S; Xu Y; Liu B; Zheng L; Cao C; Wu P; Ding W; Ren F
    Heliyon; 2023 Apr; 9(4):e14613. PubMed ID: 37035374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a prognostic model of luteolin for endometrial carcinoma.
    Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
    Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer.
    Li J; Xu W; Zhu Y
    Oncol Lett; 2020 Nov; 20(5):255. PubMed ID: 32994818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods.
    Wu R; Wu C; Zhu B; Li J; Zhao W
    Front Mol Biosci; 2023; 10():1192313. PubMed ID: 37363398
    [No Abstract]   [Full Text] [Related]  

  • 11. The Expression of Pyroptosis-Related Gene May Influence the Occurrence, Development, and Prognosis of Uterine Corpus Endometrial Carcinoma.
    Huang X; Li Y; Li J; Yang X; Xiao J; Xu F
    Front Oncol; 2022; 12():885114. PubMed ID: 35574367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
    Lu X; Jing L; Liu S; Wang H; Chen B
    Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and clinical significance of PD-1 in UCEC and its Impact on tumor.
    Xing F; Yang Y; Zheng W
    Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):168-173. PubMed ID: 37571885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
    Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
    Front Oncol; 2021; 11():766947. PubMed ID: 34868993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
    Tian Y; Wen F; Wang S; Lv N
    Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer.
    Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL
    Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.
    Xue S; Su XM; Ke LN; Huang YG
    Front Oncol; 2023; 13():1077780. PubMed ID: 36845675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
    He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
    Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
    Zheng J; Zhang YW; Pan ZF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
    Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
    Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.